Physician profile
Antonis A Markou
NPI 1700262706
$24,852.17
in general payments reported to CMS, 2019-2025
27 companies · $4,313 in 2025
The $4,313 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,169 · 2022: $2,115 · 2023: $8,526 · 2024: $7,729 · 2025: $4,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $4,413 · Travel and Lodging: $1,071 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Honoraria: $450 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,554.86 |
| Consulting Fee | $4,412.50 |
| Travel and Lodging | $1,070.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Honoraria | $450.00 |
| Education | $279.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,082.75 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $2,803.78 | 2023-2024 | Vtama |
| Leo Pharma INC. | $2,711.03 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $2,191.40 | 2022-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $1,785.21 | 2022-2025 | |
| Genzyme Corporation | $1,735.74 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,619.65 | 2021-2025 | Dupixent |
| Abbvie INC. | $1,342.46 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,074.33 | 2022-2025 | Siliq, Cabtreo, Jublia |
| Galderma Laboratories, L.P. | $860.20 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $793.77 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $734.27 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Organon LLC | $538.93 | 2025 | Vtama |
| Ucb, INC. | $432.32 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $365.92 | 2021-2024 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $322.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $281.31 | 2021-2025 | |
| Pfizer INC. | $232.65 | 2021-2022 | |
| Botanix Sb INC | $191.15 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $183.90 | 2021 | |
| Journey Medical Corporation | $154.68 | 2022 | |
| Amgen INC. | $120.65 | 2022-2023 | Otezla |
| Lilly USA, LLC | $112.40 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Vyne Pharmaceuticals INC. | $92.00 | 2021 | |
| Allergan, INC. | $42.59 | 2021 | |
| Dermira, INC. | $32.60 | 2021 | |
| Nabriva Therapeutics, Plc | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonis Markou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.